Printed From:

Estudios pivotales sobre dronedarona

  • ADONIS American–Australian–African trial with DronedarONe In atrial fibrillation or flutter for the maintenance of Sinus rhythm
  • ANDROMEDA ANtiarrhythmic trial with DROnedarone in Moderate-to-severe congestive heart failure Evaluating morbidity DecreAse
  • ATHENA A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg b.i.d. for the prevention of cardiovascular Hospitalisation or death from any cause in patiENts with Atrial fibrillation/atrial flutter
  • DAFNE Dronedarone Atrial FibrillatioN study after Electrical Cardioversion
  • DIONYSOS Randomized Double blind trIal to evaluate efficacy and safety of drOnedarone [400 mg b.i.d.] versus amiodaroNe [600 mg q.d. for 28 daYS, then 200 mg qd thereafter] for at least 6 mOnths for the maintenance of Sinus rhythm in patients with atrial fibrillation
  • ERATO Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation study.
  • EURIDIS EURopean trial In atrial fibrillation or flutter patients receiving Dronedarone for the maIntenance of Sinus rhythm.
  • PALLAS Permanent Atriall FibriLLAtion outcome Study using Dronedarone on Top Standard Therapy

 

* El tratamiento estándar puede haber incluido fármacos para el control de la frecuencia (betabloqueantes, calcioantagonistas, digoxina) tratamiento antitrombótico (antagonistas Vit. K, aspirina y otros antiagregantes plaquetarios) y / u otros fármacos CV como IECAs, ARA II y estatinas.

1 Touboul P, et al. Eur Heart J. 2003;24:1481-7.
2 Singh BN, et al. N Engl J Med. 2007;357:987-99.
3 Davy et al. Am Heart J. 2008;156:527.e1-527.e9.
4 Hohnloser SH, et al. N Engl J Med 2009;360:668-78.
5 Le Heuzey JY et al. J Cardiovasc Electrophysiol. 2010.
6 Køber L, et al. N Engl J Med. 2008;358:2678-87.
7
Connolly SJ et al. N Engl J Med 2011 December 15, 2011;365:2268-76

Área para Profesionales

Perfil